Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-Transferase, and epoxide hydrolase enzymes:: Relevance to xenobiotic metabolism and toxicity

被引:237
作者
Wormhoudt, LW [1 ]
Commandeur, JNM [1 ]
Vermeulen, NPE [1 ]
机构
[1] Free Univ Amsterdam, Leiden Amsterdam Ctr Drug Res, Div Mol Toxicol, Dept Pharmacochem, NL-1081 HV Amsterdam, Netherlands
关键词
genetic polymorphisms; biotransformation; enzymes; metabolism; toxicology; inter-individual variability;
D O I
10.1080/10408449991349186
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
In this review, an overview is presented of the current knowledge of genetic polymorphisms of four of the most important enzyme families involved in the metabolism of xenobiotics, that is, the N-acetyltransferase (NAT), cytochrome P450 (P450), glutathione-S-transferase (GST), and microsomal epoxide hydrolase (mEH) enzymes. The emphasis is on two main topics, the molecular genetics of the polymorphisms and the consequences for xenobiotic metabolism and toxicity. Studies are described in which wild-type and mutant alleles of biotransformation enzymes have been expressed in heterologous systems to study the molecular genetics and the metabolism and pharmacological or toxicological effects of xenobiotics. Furthermore, studies are described that have investigated the effects of genetic polymorphisms of biotransformation enzymes on the metabolism of drugs in humans and on the metabolism of genotoxic compounds in vivo as well. The effects of the polymorphisms are highly dependent on the enzyme systems involved and the compounds being metabolized. Several polymorphisms are described that also clearly influence the metabolism and effects of drugs and toxic compounds, in vivo in humans. Future perspectives in studies on genetic polymorphisms of biotransformation enzymes are also discussed. It is concluded that genetic polymorphisms of biotransformation enzymes are in a number of cases a major factor involved in the interindividual variability in xenobiotic metabolism and toxicity. This may lead to interindividual variability in efficacy of drugs and disease susceptibility.
引用
收藏
页码:59 / 124
页数:66
相关论文
共 531 条
[51]   ENANTIOSELECTIVE AMITRIPTYLINE METABOLISM IN PATIENTS PHENOTYPED FOR 2 CYTOCHROME-P450 ISOZYMES [J].
BREYERPFAFF, U ;
PFANDL, B ;
NILL, K ;
NUSSER, E ;
MONNEY, C ;
JONZIERPEREY, M ;
BAETTIG, D ;
BAUMANN, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (04) :350-358
[52]  
BROCKMOLLER J, 1993, CANCER RES, V53, P1004
[53]  
BROCKMOLLER J, 1995, PHARMACOGENETICS, V5, P80
[54]  
Brockmoller J, 1996, CANCER RES, V56, P3915
[55]   DEBRISOQUINE OXIDATION POLYMORPHISM - PHENOTYPIC CONSEQUENCES OF A 3-BASE-PAIR DELETION IN EXON 5 OF THE CYP2D6 GENE [J].
BROLY, F ;
MEYER, UA .
PHARMACOGENETICS, 1993, 3 (03) :123-130
[56]   An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis [J].
Broly, F ;
Marez, D ;
Sabbagh, N ;
Legrand, M ;
Millecamps, S ;
LoGuidice, JM ;
Boone, P ;
Meyer, UA .
PHARMACOGENETICS, 1995, 5 (06) :373-384
[57]   A NONSENSE MUTATION IN THE CYTOCHROME-P450 CYP2D6 GENE IDENTIFIED IN A CAUCASIAN WITH AN ENZYME DEFICIENCY [J].
BROLY, F ;
MAREZ, D ;
LOGUIDICE, JM ;
SABBAGH, N ;
LEGRAND, M ;
BOONE, P ;
MEYER, UA .
HUMAN GENETICS, 1995, 96 (05) :601-603
[58]   DEBRISOQUINE SPARTEINE HYDROXYLATION GENOTYPE AND PHENOTYPE - ANALYSIS OF COMMON MUTATIONS AND ALLELES OF CYP2D6 IN A EUROPEAN POPULATION [J].
BROLY, F ;
GAEDIGK, A ;
HEIM, M ;
EICHELBAUM, M ;
MORIKE, K ;
MEYER, UA .
DNA AND CELL BIOLOGY, 1991, 10 (08) :545-558
[59]   IMIPRAMINE DEMETHYLATION AND HYDROXYLATION - IMPACT OF THE SPARTEINE OXIDATION PHENOTYPE [J].
BROSEN, K ;
OTTON, SV ;
GRAM, LF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (05) :543-549
[60]   STEADY-STATE CONCENTRATIONS OF IMIPRAMINE AND ITS METABOLITES IN RELATION TO THE SPARTEINE DEBRISOQUINE POLYMORPHISM [J].
BROSEN, K ;
KLYSNER, R ;
GRAM, LF ;
OTTON, SV ;
BECH, P ;
BERTILSSON, L .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (06) :679-684